Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1

.

Source: Expert Opinion on Therapeutic Patents - June 21, 2019 Category: Drugs & Pharmacology Authors: Martin Perez-Santos Maricruz Anaya-Ruiz Irma Herrera-Camacho Lourdes Mill án-Pérez Peña Source Type: research